2m 2m 2m 2m 2m 2m 2m
FENNEC PHARMA (FENC)
NASDAQ
$9.14-$0.005 (-0.05%)
Price as of Jun 03, 2026 7:46 PM EDT- $343.0MMarket Cap
- 19.09%1-Year Change
- BiotechnologyIndustry
FENNEC PHARMA (FENC)
$9.14-$0.005 (-0.05%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 44.6M -6.09% | 47.5M +123.69% | 21.3M +1,284.50% | 1.5M +802.94% | |
Cost of Revenue | N/A N/A | N/A N/A | 1.3M +1,363.95% | 86,000 N/A | |
Gross Profit | 44.6M -6.09% | 47.5M +137.77% | 20.0M +1,279.78% | 1.4M +752.35% | |
Sales and Marketing Expense | 18.6M +1.03% | 18.4M +51.99% | 12.1M +335.30% | 2.8M N/A | |
Research and Development Expense | -250,000 -18.57% | -307,000 +448.21% | -56,000 -98.41% | -3.5M -29.11% | |
Depreciation and Amortization Expense | 103,000 -87.12% | 800,000 N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 50.9M +13.24% | 45.0M +37.25% | 32.8M +36.30% | 24.0M +39.57% | |
Operating Profit | -6.3M -344.63% | 2.6M +120.11% | -12.8M -43.46% | -22.6M +31.16% | |
Interest Income | 787,000 -53.21% | 1.7M N/A | N/A N/A | 195,000 +261.11% | |
Interest Expense | -2.1M -48.88% | -4.1M N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -1.3M -45.83% | -2.4M N/A | 0 -100.00% | 195,000 +261.11% | |
Total Nonoperating Income and Expense | -3.4M +27.06% | -2.6M -19.40% | -3.3M +191.02% | -1.1M +814.63% | |
Income before Taxes | -9.6M +13,470.42% | -71,000 -99.44% | -12.8M -43.46% | -22.6M +31.16% | |
Income Taxes | 106,000 -70.96% | 365,000 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -9.7M +2,134.17% | -436,000 -97.28% | -16.0M -32.34% | -23.7M +36.71% | |
Net Income from Continuing Operations Applicable to Common | -9.6M +13,470.42% | -71,000 -99.56% | -16.0M -32.34% | -23.7M +36.71% | |
Basic EPS and Net Income | -0.34 +1,600.00% | -0.02 -96.67% | -0.60 -33.33% | -0.90 +34.33% | |
Diluted EPS and Net Income | -0.34 +1,600.00% | -0.02 -96.67% | -0.60 -33.33% | -0.90 +34.33% | |
Basic Weighted Average Shares | 28.6M +4.70% | 27.3M +2.71% | 26.6M +1.14% | 26.3M +100,934.38% | |
Diluted Weighted Average Shares | 28.6M +4.70% | 27.3M +2.71% | 26.6M +1.14% | 26.3M +100,934.38% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 36.8M +38.12% | 26.6M +100.72% | 13.3M -44.19% | 23.8M +12.67% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 36.8M +38.12% | 26.6M +100.72% | 13.3M -44.19% | 23.8M +12.67% | |
Total Current Assets | 67.0M +51.94% | 44.1M +64.29% | 26.9M +0.49% | 26.7M +19.39% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 3.5M +326.76% | 822,000 +13,600.00% | 6,000 -97.16% | 211,000 +681.48% | |
Total Assets | 70.6M +56.97% | 44.9M +67.31% | 26.9M -0.28% | 26.9M +20.19% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 10.5M +52.02% | 6.9M -8.39% | 7.6M +63.88% | 4.6M +178.66% | |
Total Long-Term Debt | 0 -100.00% | 19.3M -37.48% | 30.9M +24.23% | 24.9M +399.18% | |
Total Long-Term Liabilities | 24.6M -44.05% | 43.9M +41.92% | 30.9M +24.23% | 24.9M +399.18% | |
Total Liabilities | 35.1M -30.97% | 50.8M +32.04% | 38.5M +30.43% | 29.5M +344.26% | |
Retained Earnings | -229.4M +4.43% | -219.7M +0.20% | -219.2M +7.90% | -203.2M +13.21% | |
Total Stockholders Equity | 35.5M +704.09% | -5.9M -49.48% | -11.6M +352.39% | -2.6M -116.29% | |
Total Shares Outstanding | 34.2M +24.11% | 27.5M +1.85% | 27.0M +2.53% | 26.4M +1.33% | |
Cash Flow | |||||
Cash from Operating Activities | -12.5M -146.23% | 27.0M +257.38% | -17.1M -5.07% | -18.1M +26.97% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 22.6M +266.19% | -13.6M -305.11% | 6.6M -67.98% | 20.7M +316.47% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | 94.08% -0.34% | 94.40% N/A | |
Operating Margin | -14.07% -360.50% | 5.40% +108.99% | -60.09% -95.92% | -1,471.60% -85.47% | |
Return on Assets | -16.87% +1,289.11% | -1.21% -97.96% | -59.64% -37.94% | -96.10% +49.12% | |
Return on Equity | -65.82% -1,420.42% | 4.98% -97.80% | 226.13% +162.95% | -359.22% +364.32% | |
Revenue Growth | -6.09% -104.93% | 123.69% -90.37% | 1,284.50% +59.97% | 802.94% +1,585.44% | |
Current Ratio | 6.37 -0.05% | 6.38 +79.34% | 3.56 -38.68% | 5.80 -57.16% | |
Cash Ratio | 3.50 -9.14% | 3.85 +119.11% | 1.76 -65.94% | 5.16 -59.57% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow